Your browser is no longer supported. Please, upgrade your browser.
Settings
VCNX Vaccinex, Inc. daily Stock Chart
VCNX [NASD]
Vaccinex, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own4.40% Shs Outstand15.15M Perf Week12.59%
Market Cap96.20M Forward P/E- EPS next Y-2.78 Insider Trans0.00% Shs Float11.04M Perf Month25.00%
Income-34.00M PEG- EPS next Q-0.58 Inst Own58.70% Short Float1.03% Perf Quarter38.04%
Sales0.70M P/S137.43 EPS this Y-34.60% Inst Trans-0.08% Short Ratio4.40 Perf Half Y29.61%
Book/sh-1.46 P/B- EPS next Y-4.50% ROA-255.30% Target Price21.33 Perf Year25.99%
Cash/sh0.57 P/C11.19 EPS next 5Y- ROE187.10% 52W Range3.77 - 12.23 Perf YTD30.93%
Dividend- P/FCF- EPS past 5Y- ROI344.90% 52W High-48.08% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin30.30% 52W Low68.57% ATR0.92
Employees44 Current Ratio1.50 Sales Q/Q100.00% Oper. Margin- RSI (14)54.50 Volatility10.87% 20.10%
OptionableNo Debt/Eq- EPS Q/Q3.40% Profit Margin- Rel Volume0.85 Prev Close5.51
ShortableYes LT Debt/Eq- EarningsNov 12 Payout- Avg Volume25.90K Price6.35
Recom- SMA20-2.38% SMA5011.33% SMA20012.27% Volume21,900 Change15.25%
Sep-04-18Initiated Ladenburg Thalmann Buy $22
Feb-06-20 07:31AM  Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Dec-10-19 08:02AM  Vaccinex Announces $3 Million Award from the Alzheimers Drug Discovery Foundation GlobeNewswire
Dec-09-19 07:55AM  Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimers Disease GlobeNewswire
Nov-25-19 07:18PM  Is Vaccinex, Inc. (VCNX) Burning These Hedging Funds ? Insider Monkey +5.28%
Nov-14-19 07:55AM  Vaccinex Announces Award Notice from the Alzheimers Association 2020 Part the Cloud Program GlobeNewswire
Nov-12-19 08:00AM  Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +12.03%
Nov-09-19 08:02AM  Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire
Oct-31-19 09:14AM  Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board GlobeNewswire
Sep-27-19 06:05AM  Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France GlobeNewswire -5.74%
Sep-24-19 08:05AM  Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire +10.29%
Sep-06-19 10:45AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX GlobeNewswire
Aug-14-19 12:18PM  Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study Zacks
08:30AM  Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-13-19 08:05AM  Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer GlobeNewswire
Aug-12-19 05:49PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX GlobeNewswire
Aug-02-19 01:41PM  Insiders Roundup: Bezos Sells Amazon GuruFocus.com +8.86%
Aug-01-19 09:15AM  Vaccinex Inc (VCNX) President and CEO Maurice Zauderer Bought $750,002 of Shares GuruFocus.com
Jul-31-19 07:30AM  Vaccinex Announces $13.8 Million Private Placement GlobeNewswire
Jun-03-19 08:00AM  Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting GlobeNewswire -6.78%
May-15-19 08:10AM  Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting GlobeNewswire
08:05AM  Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-09-19 08:30AM  Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire
Apr-01-19 08:00AM  Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire +22.62%
Mar-13-19 08:30AM  Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019 GlobeNewswire -6.98%
07:16AM  Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-06-19 08:30AM  Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Jan-17-19 08:30AM  Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntingtons Disease (the SIGNAL Trial) at Cambridge Healthtech Institutes 18th Annual PepTalk GlobeNewswire
Jan-16-19 08:30AM  Vaccinex, Inc. Announces Completion of Enrollment for Its SIGNAL Huntingtons Disease Trial GlobeNewswire +21.16%
Dec-12-18 12:18PM  Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)? Simply Wall St. -12.38%
08:30AM  Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research GlobeNewswire
Nov-27-18 07:30AM  Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event ACCESSWIRE
Nov-15-18 08:30AM  Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Nov-13-18 07:58AM  Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +6.02%
Nov-12-18 08:30AM  Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntingtons Disease at the Huntington Study Groups 2018 Annual Meeting GlobeNewswire
Nov-06-18 08:30AM  Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntingtons Disease GlobeNewswire
Oct-23-18 08:30AM  Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018 GlobeNewswire
Oct-02-18 08:30AM  Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-27-18 08:30AM  Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-25-18 08:30AM  Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire -5.21%
Sep-13-18 01:05PM  Why Did Vaccinex Incs (NASDAQ:VCNX) Insiders Buy Up More Shares? Simply Wall St.
Sep-04-18 11:12AM  Oppenheimer: Vaccinex Has Catalysts In Novel Therapies For Challenging Diseases Benzinga
Aug-09-18 10:52AM  Vaccinex shares slide 3% on their first day of trade MarketWatch
09:39AM  Vaccinex prices IPO at $12, low end of price range MarketWatch
09:08AM  Vaccinex Announces Pricing of Initial Public Offering GlobeNewswire
Aug-05-18 09:48AM  The IPO Outlook For The Week: An Airline, A Biotech And 2 Banks Benzinga
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.